Stock Track | Avanos Medical Plunges Over 10% in Pre-Market on Dismal Q4 Results and Weak Guidance

Stock Track

Feb 26, 2025

Avanos Medical Inc. (AVNS) stock plummeted more than 10% in the pre-market trading session on Wednesday, following the release of the company's disappointing fourth-quarter results and underwhelming guidance for the full year.

The medical technology company reported a staggering net loss of $397.3 million for the fourth quarter, with an operating loss of $418.5 million and an EBITDA loss of $407.6 million. Despite generating $179.6 million in sales, Avanos Medical's gross profit stood at a mere $98 million, reflecting the company's significant operational challenges.

Adding to the concerns, Avanos Medical provided a lackluster earnings guidance for the full year, projecting an adjusted EPS range of $1.05 to $1.25, significantly lower than market expectations. The company's weak outlook further exacerbated investors' concerns about its future prospects, contributing to the pre-market sell-off.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1171304593"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171304593\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171304593?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171304593","market":"hk","top_or_hot":-1,"title":"Stock Track | Avanos Medical Plunges Over 10% in Pre-Market on Dismal Q4 Results and Weak Guidance","media":"Stock Track","content":"<p>Avanos Medical Inc. (AVNS) stock plummeted more than 10% in the pre-market trading session on Wednesday, following the release of the company's disappointing fourth-quarter results and underwhelming guidance for the full year.</p>\n\n<p>The medical technology company reported a staggering net loss of $397.3 million for the fourth quarter, with an operating loss of $418.5 million and an EBITDA loss of $407.6 million. Despite generating $179.6 million in sales, Avanos Medical's gross profit stood at a mere $98 million, reflecting the company's significant operational challenges.</p>\n\n<p>Adding to the concerns, Avanos Medical provided a lackluster earnings guidance for the full year, projecting an adjusted EPS range of $1.05 to $1.25, significantly lower than market expectations. The company's weak outlook further exacerbated investors' concerns about its future prospects, contributing to the pre-market sell-off.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Avanos Medical Plunges Over 10% in Pre-Market on Dismal Q4 Results and Weak Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Avanos Medical Plunges Over 10% in Pre-Market on Dismal Q4 Results and Weak Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Avanos Medical Inc. (AVNS) stock plummeted more than 10% in the pre-market trading session on Wednesday, following the release of the company's disappointing fourth-quarter results and underwhelming guidance for the full year.</p>\n\n<p>The medical technology company reported a staggering net loss of $397.3 million for the fourth quarter, with an operating loss of $418.5 million and an EBITDA loss of $407.6 million. Despite generating $179.6 million in sales, Avanos Medical's gross profit stood at a mere $98 million, reflecting the company's significant operational challenges.</p>\n\n<p>Adding to the concerns, Avanos Medical provided a lackluster earnings guidance for the full year, projecting an adjusted EPS range of $1.05 to $1.25, significantly lower than market expectations. The company's weak outlook further exacerbated investors' concerns about its future prospects, contributing to the pre-market sell-off.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVNS","symbol_name":"AVANOS MEDICAL","start_time":0,"source_url":"","article_id":"1171304593","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171304593","pubTimestamp":1740571940,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Avanos Medical Inc.  stock plummeted more than 10% in the pre-market trading session on Wednesday, following the release of the company's disappointing fourth-quarter results and underwhelming guidance for the full year.The medical technology company reported a staggering net loss of $397.3 million for the fourth quarter, with an operating loss of $418.5 million and an EBITDA loss of $407.6 million. Despite generating $179.6 million in sales, Avanos Medical's gross profit stood at a mere $98 mil","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVNS":"AVANOS MEDICAL"},"translate_title":"由于第四季度业绩惨淡和指引疲弱，Avanos Medical盘前暴跌逾10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVNS":1},"content_text":"Avanos Medical Inc. (AVNS) stock plummeted more than 10% in the pre-market trading session on Wednesday, following the release of the company's disappointing fourth-quarter results and underwhelming guidance for the full year.\nThe medical technology company reported a staggering net loss of $397.3 million for the fourth quarter, with an operating loss of $418.5 million and an EBITDA loss of $407.6 million. Despite generating $179.6 million in sales, Avanos Medical's gross profit stood at a mere $98 million, reflecting the company's significant operational challenges.\nAdding to the concerns, Avanos Medical provided a lackluster earnings guidance for the full year, projecting an adjusted EPS range of $1.05 to $1.25, significantly lower than market expectations. The company's weak outlook further exacerbated investors' concerns about its future prospects, contributing to the pre-market sell-off.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}